Eisai and Biogen have launched Leqembi, their anti-amyloid beta monoclonal antibody, in Austria and Germany, marking the drug’s first entry into the European Union market. This follows the European Commission’s April 2025 approval, positioning Leqembi as the first therapy to address an underlying cause of Alzheimer’s disease. The launch is restricted to adult patients with early-stage Alzheimer’s (mild cognitive impairment or mild dementia) who are either non-carriers or heterozygotes of the APOE ε4 gene, a genetic variant associated with increased risk of amyloid-related imaging abnormalities (ARIA). This targeted approach reflects the need to balance the drug’s potential benefits with the risk of ARIA, particularly in patients with two copies of the APOE ε4 gene.
The controlled access program now in place in Austria and Germany highlights the complexities of introducing a novel Alzheimer’s therapy. This program not only restricts access but also underscores the cautious approach being taken by regulators and healthcare systems as they grapple with the clinical and economic implications of this new class of treatments. The program also emphasizes the importance of real-world data collection to refine further our understanding of Leqembi’s long-term efficacy and safety profile.
This European launch represents a pivotal moment in the Alzheimer’s treatment landscape. For years, the focus has been on managing symptoms, but Leqembi, by targeting both amyloid plaque and protofibrils, aims to modify the disease’s progression. This shift toward disease modification has significant implications for patients, healthcare providers, and the broader healthcare system. The rollout of Leqembi requires extensive education for healthcare professionals on patient selection, monitoring for ARIA, and managing expectations.
The commercial success of Leqembi will depend heavily on payer acceptance and pricing negotiations, especially given the complexities of administering the treatment and monitoring for side effects. The market access strategies employed by Eisai and Biogen will be closely scrutinized by other companies developing similar therapies. The initial launch in Austria and Germany serves as a crucial test case for navigating these commercial challenges and establishing a framework for future launches in other European markets.
The long-term impact of Leqembi on the Alzheimer’s treatment paradigm remains to be seen. While the CLARITY AD trial data demonstrate a statistically significant slowing of cognitive decline, the clinical meaningfulness of this effect in patients’ daily lives will be a key factor in determining the drug’s ultimate value. Furthermore, questions remain regarding the long-term safety profile, optimal treatment duration, and the potential for combination therapies with other emerging Alzheimer’s drugs. The evolution of the market will depend on the answers to these questions, making ongoing research and data collection essential.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
